Sangamo Therapeutics (SGMO) Set to Announce Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) will be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The company had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $0.54 on Wednesday. The business’s fifty day moving average is $0.68 and its 200 day moving average is $0.59. Sangamo Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $1.67. The company has a market capitalization of $112.03 million, a PE ratio of -0.37 and a beta of 1.40.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SGMO shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Saturday, April 27th. They issued a “sell” rating for the company. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.67.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.